恩格列净治疗2型糖尿病和心肾获益的研究进展  

Research progress of empagliflozin in the treatment of type 2 diabetes mellitus and cardiovascular and renal benefits

作　　者：刘子涵 杜文雨 郭彩会[2] 王智[2] 李颖[2] 董占军[2] LIU Zihan;DU Wenyu;GUO Caihui;WANG Zhi;LI Ying;DONG Zhanjun(Graduate School of Hebei Medical University,Shijiazhuang 050017,Hebei,China;Department of Pharmacy,Hebei General Hospital,Hebei Provincial Key Laboratory of Clinical Pharmacy,Shijiazhuang 050051,Hebei,China)

机构地区：[1]河北医科大学研究生学院,河北石家庄050017 [2]河北省人民医院药学部,河北省临床药学重点实验室,河北石家庄050051

出　　处：《中国临床药理学与治疗学》2025年第3期412-418,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：河北省医学科学研究课题(20210037)。

摘　　要：2型糖尿病(type 2 diabetes mellitus,T2DM)是一种胰岛素抵抗疾病,改善胰岛素抵抗及控制血糖是临床治疗T2DM的主要手段。恩格列净是一种高选择性的钠-葡萄糖协同转运蛋白(sodium-dependent glucose transporters,SGLT)2受体抑制剂,不依赖于胰岛素,在有效控制血糖水平的同时,还可降低患者血压和体质量,保护心肾功能,降低心衰(heart failure,HF)患者再住院率和死亡风险,且不会增加低血糖的风险,可单独给药,也可以联合其他降糖药物控制血糖。本文就恩格列净的作用机制、临床获益、与其他药物联合应用等方面进行综述,旨在为恩格列净的临床应用提供参考。Type 2 diabetes mellitus(T2DM)is an insulin resistance disease.Improving insulin resistance and controlling blood glucose are the main means of clinical treatment for T2DM.Empagliflozin is a highly selective sodium-dependent glucose transporters(SGLT)2 inhibitor,which is independent of insulin.It can effectively control blood glucose levels,reduce blood pressure and body weight,protect heart and kidney function,reduce the rehospitalization rate and the risk of death in patients with heart failure(HF),and does not increase the risk of hypoglycemia.Empagliflozin can be used alone or in combination with other hypoglycemic drugs to control blood glucose.This article reviews the mechanism of action,clinical benefits,and combination with other drugs of empagliflozin,aiming to provide reference for the clinical use of empagliflozin.

关 键 词：恩格列净 2型糖尿病 心力衰竭 慢性肾脏病 

分 类 号：R58[医药卫生—内分泌]